Stockreport

Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome

Karyopharm Therapeutics Inc.  (KPTI) 
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.karyopharm.com/investor-relations
PDF NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, tod [Read more]